Rosy projections from the Trump administration may give savers inflated expectations about the wealth-building power of the ...

SPXL sells a simple promise: three times the daily move of the S&P 500. What its factsheet does not sell is the quiet gap that opens between that promise and reality every time markets zigzag. That ...

A $450-a-month habit adds up to $162,000 over 30 years. But if those contributions are modelled as $5,400 a year and ...

Learn how CDs pay compound interest and how it affects their annual percentage yield (APY) to maximize your savings strategy ...

Gen Z's 13-year head start over Boomers looks decisive on paper, yet one economic force is quietly eroding it before the first decade of saving is even complete. See the compounding math → Gen Z ...

A 25 year old who invests $5,000 a year for a decade and then never contributes another dollar ends up with $426,000 more at age 65 than someone who waits until 35 and does the exact same thing. Same ...

Share on Pinterest The FDA puts forward a move to exclude GLP-1 drugs from the bulk compounding list. Image credit: VICTOR TORRES/Stocksy On April 30, 2026, the U.S. FDA announced it is considering ...

If you're waiting to start investing, you're leaving lots of money on the table. Here's how to stop the bleeding.

The Food and Drug Administration on April 30 proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...